देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
Febuxostat
Rowex Ltd
M04AA; M04AA03
Febuxostat
80 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
Preparations inhibiting uric acid production; febuxostat
Marketed
2017-07-14
PACKAGE LEAFLET: INFORMATION FOR THE USER _ _ FEBUXOSTAT ROWEX 80 MG FILM-COATED TABLETS FEBUXOSTAT ROWEX 120 MG FILM-COATED TABLETS febuxostat READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. _ _ WHAT IS IN THIS LEAFLET 1. What Febuxostat Rowex is and what it is used for 2. What you need to know before you take Febuxostat Rowex 3. How to take Febuxostat Rowex 4. Possible side effects 5. How to store Febuxostat Rowex 6. Contents of the pack and other information 1. WHAT FEBUXOSTAT ROWEX IS AND WHAT IT IS USED FOR Febuxostat Rowex tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body. In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble. When this happens, urate crystals may form in and around the joints and kidneys. These crystals can cause sudden, severe pain, redness, warmth and swelling in a joint (known as a gout attack). Left untreated, larger deposits called tophi may form in and around joints. These tophi may cause joint and bone damage. Febuxostat Rowex works by reducing uric acid levels. Keeping uric acid levels low by taking Febuxostat Rowex once every day stops crystals building up, and over time it reduces symptoms. Keeping uric acid levels sufficiently low for a long enough period can also shrink tophi. _Febuxostat Rowex 120 mg: _ Febuxostat Rowex 120 mg Film-coated tablets are also used to treat and prevent high blood levels of uric acid that may occur when पूरा दस्तावेज़ पढ़ें
Health Products Regulatory Authority 16 January 2024 CRN00DV0Q Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Febuxostat Rowex 80 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 80 mg of febuxostat (as hemihydrate). Excipient(s) with known effect: Each film-coated tablet contains 72.68 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Pale yellow to yellow, film-coated, capsule shaped tablets, engraved with "80" on one side and plain on the other, with dimensions 16.5 mm x 7.0 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Febuxostat Rowex is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Rowex is indicated in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Gout: _The recommended oral dose of Febuxostat Rowex is 80 mg once daily without regard to food. If serum uric acid is > 6 mg/dL (357 micromol/L) after 2-4 weeks, Febuxostat Rowex 120 mg once daily may be considered. Febuxostat Rowex works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 micromol/L). Gout flare prophylaxis of at least 6 months is recommended (see section 4.4). _Elderly_ No dose adjustment is required in the elderly (see section 5.2). _Renal impairment_ The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see section 5.2). No dose adjustment is necessary in patients with mild or moderate renal impairment. _Hepatic impairment_ The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment (Child Pugh Class C). _Gout:_ The recommended dose in patients with mild hepatic impairment is 80 mg. Limited infor पूरा दस्तावेज़ पढ़ें